Reassessing the NTCTCS staging systems for differentiated thyroid cancer, including age at diagnosis

Thyroid

Volumn 25, Issue 10, 2015, Pages 1097-1105

  Mcleod, Donald S A ^a,b,c   Jonklaas, Jacqueline ^d   Brierley, James D ^e   Ain, Kenneth B ^f   Cooper, David S ^g   Fein, Henry G ^h   Haugen, Bryan R ⁱ   Ladenson, Paul W ^g   Magner, James ^j   Ross, Douglas S ^k   Skarulis, Monica C ^l   Steward, David L ^m   Xing, Mingzhao ^g   Litofsky, Danielle R ⁿ   Maxon, Harry R ^m   Sherman, Steven I ⁿ  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f UNIVERSITY OF KENTUCKY   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h SINAI HOSPITAL OF BALTIMORE   (United States)

ⁱ UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^j GENZYME CORPORATION   (United States)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

^l NATIONAL INSTITUTES OF HEALTH   (United States)

^m UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

ⁿ UNIVERSITY OF TEXAS   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CERVICAL LYMPH NODE; DIFFERENTIATED THYROID CANCER; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NATIONAL THYROID CANCER TREATMENT COOPERATIVE STUDY STAGING SYSTEM; ONCOCYTOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; THYROID FOLLICULAR CARCINOMA; TUMOR VOLUME; ADENOCARCINOMA; AGE; AGED; MIDDLE AGED; ONSET AGE; PAPILLARY CARCINOMA; PATHOLOGY; PROGNOSIS; THYROID GLAND; THYROID TUMOR;

ADENOCARCINOMA, FOLLICULAR; ADULT; AGE FACTORS; AGE OF ONSET; AGED; CARCINOMA, PAPILLARY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; THYROID GLAND; THYROID NEOPLASMS;

EID: 84942811688     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2015.0148     Document Type: Article

References (34)

1. Crile G Jr, Hazard JB 1953 Relationship of the age of the patient to the natural history and prognosis of carcinoma of the thyroid. Ann Surg 138: 33-38
2. Woolner LB, Beahrs OH, Black BM, Mc CW, Keating FR Jr 1961 Classification and prognosis of thyroid carcinoma. A study of 885 cases observed in a thirty year period. Am J Surg 102: 354-387
3. Halnan KE 1966 Influence of age and sex on incidence and prognosis of thyroid cancer. Three hundred forty-four cases followed for ten years. Cancer 19: 1534-1536
4. Byar DP, Green SB, Dor P, Williams ED, Colon J, Van Gilse HA, Mayer M, Sylvester RJ, Van Glabbeke M 1979A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. Eur J Cancer 15: 1033-1041
5. Franssila KO 1975 Prognosis in thyroid carcinoma. Cancer 36: 1138-1146
6. Beahrs OH, Myers MH 1983 Manual for Staging of Cancer. Second edition. Lippincott, Williams, & Wilkins, Philadelphia, P.A.
7. Tubiana M, Schlumberger M, Rougier P, Laplanche A, Benhamou E, Gardet P, Caillou B, Travagli JP, Parmentier C 1985 Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 55: 794-804
8. Sherman SI, Brierley JD, Sperling M, Ain KB, Bigos ST, Cooper DS, Haugen BR, Ho M, Klein I, Ladenson PW, Robbins J, Ross DS, Specker B, Taylor T, Maxon HR 3rd 1998 Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group Cancer 83: 1012-1021
9. Jonklaas J, Nogueras-Gonzalez G, Munsell M, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman SI 2012 The impact of age and gender on papillary thyroid cancer survival. J Clin Endocrinol Metab 97: E878-887
10. Tran Cao HS, Johnston LE, Chang DC, Bouvet M 2012A critical analysis of the American Joint Committee on Cancer (AJCC) staging system for differentiated thyroid carcinoma in young patients on the basis of the Surveillance, Epidemiology, and End Results (SEER) registry. Surgery 152: 145-151
11. Bischoff LA, Curry J, Ahmed I, Pribitkin E, Miller JL 2013 Is above age 45 appropriate for upstaging welldifferentiated papillary thyroid cancer?. Endocr Pract 19: 995-997
12. Mazurat A, Torroni A, Hendrickson-Rebizant J, Benning H, Nason RW, Pathak KA 2013 The age factor in survival of a population cohort of well differentiated thyroid cancer. Endocr Connect 2: 154-160
13. Micheli A, Ciampichini R, Oberaigner W, Ciccolallo L, De Vries E, Izarzugaza I, Zambon P, Gatta G, De Angelis R, Group EW 2009 The advantage of women in cancer survival: an analysis of EUROCARE-4 data. Eur J Cancer 45: 1017-1027
14. Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, Ain KB, Bigos ST, Brierley JD, Haugen BR, Klein I, Robbins J, Sherman SI, Taylor T, Maxon HR 3rd 1998 Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 8: 737-744
15. Taylor T, Specker B, Robbins J, Sperling M, Ho M, Ain K, Bigos ST, Brierley J, Cooper D, Haugen B, Hay I, Hertzberg V, Klein I, Klein H, Ladenson P, Nishiyama R, Ross D, Sherman S, Maxon HR 1998 Outcome after treatment of high-risk papillary and non-Hürthle-cell follicular thyroid carcinoma. Ann Intern Med 129: 622-627
16. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis M, Maxon HR, Sherman SI 2006 Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 16: 1229-1242
17. Ross DS, Litofsky D, Ain KB, Bigos T, Brierley JD, Cooper DS, Haugen BR, Jonklaas J, Ladenson PW, Magner J, Robbins J, Skarulis MC, Steward DL, Maxon HR, Sherman SI 2009 Recurrence after treatment of micropapillary thyroid cancer. Thyroid 19: 1043-1048
18. Jonklaas J, Cooper DS, Ain KB, Bigos T, Brierley JD, Haugen BR, Ladenson PW, Magner J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman SI 2010 Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid 20: 1423-1424
19. McLeod DS, Cooper DS, Ladenson PW, Ain KB, Brierley JD, Fein HG, Haugen BR, Jonklaas J, Magner J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman SI 2014 Prognosis of differentiated thyroid cancer in relation to serum TSH and thyroglobulin antibody status at time of diagnosis. Thyroid 24: 35-42
20. Carhill AA, Litofsky DR, Ross DS, Jonklaas J, Cooper DS, Brierley JD, Ladenson PW, Ain KB, Fein HG, Haugen BR, Magner J, Skarulis MC, Steward DL, Xing M, Maxon HR, Sherman SI 2015 Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS Registry Analysis 1987-2012. J Clin Endocrinol Metab [Epub ahead of print]; JC20151346
21. Harrell FE, Jr., Califf RM, Pryor DB, Lee KL, Rosati RA 1982 Evaluating the yield of medical tests. JAMA 247: 2543-2546
22. Efron B 1979 Bootstrap methods: another look at the jackknife. Ann Stat 7: 1-26
23. Hosmer DW, Lemeshow S, May S 2008 Applied Survival Analysis: Regression Modeling of Time-to-Event Data. Second edition. Wiley-Interscience, Hoboken, N.J.
24. Kazaure HS, Roman SA, Sosa JA 2012 Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43, 738 patients. Ann Surg Oncol 19: 1874-1880
25. Harrell FE 2001 Regression Modeling Strategies With Applications to Linear Models, Logistic Regression, and Survival Analysis. Springer-Verlag, New York, N.Y.
26. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS 1993 Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114: 1050-1057; discussion 1057-1058
27. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A 2010 Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20: 1341-1349
28. Johnson TL, Lloyd RV, Thompson NW, Beierwaltes WH, Sisson JC 1988 Prognostic implications of the tall cell variant of papillary thyroid carcinoma. Am J Surg Pathol 12: 22-27
29. Morris LG, Shaha AR, Tuttle RM, Sikora AG, Ganly I 2010 Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival. Thyroid 20: 153-158
30. Elaraj DM, Clark OH 2007 Changing management in patients with papillary thyroid cancer. Curr Treat Options Oncol 8: 305-313
31. Nixon IJ, Ganly I, Patel SG, Palmer FL, Whitcher MM, Ghossein R, Michael Tuttle R, Shaha AR, Shah JP 2012 Changing trends in well differentiated thyroid carcinoma over eight decades. Int J Surg 10: 618-623
32. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, De la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Pena C, Molnar I, Schlumberger MJ, investigators D 2014 Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384: 319-328
33. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, De las Heras B, Zhu J, Sherman SI 2015 Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. New Engl J Med 372: 621-630
34. Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S, Ghossein RA, Ricarte-Filho JC, Dominguez JM, Shen R, Tuttle RM, Larson SM, Fagin JA 2013 Selumetinibenhanced radioiodine uptake in advanced thyroid cancer. New Engl J Med 368: 623-632